Showing 6341-6350 of 7021 results for "".
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142
- Allergan Completes Acquisition of Kybella Maker Kytherahttps://practicaldermatology.com/news/allergan-completes-acquisition-of-kybella-maker-kythera/2458856/Allergan plc has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion. The acquisition of Kythera adds Kybella® (deoxych
- Novan's SB204 Demonstrates Positive Phase 2b Clinical Trial Results for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/novans-sb204-demonstrates-positive-phase-2b-clinical-trial-results-for-the-treatment-of-acne-vulgaris/2458863/Novan Therapeutics topical nitric oxide drug candidate SB204 for the treatment of acne vulgaris, demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and
- DermTube Offers Video Coverage of NewDerm Live Meetinghttps://practicaldermatology.com/news/dermtube-offers-video-coverage-of-newderm-live-meeting/2458865/NewDerm LIVE, a new meeting for dermatologists just starting out in practice—as well as those not so new to practice—has brought a unique meeting format into the dermatology space. The meeting, supported by the publishers of Practical Dermatology® magazine and NewDerm
- The Osteopathic Dermatologist: Dr. Peter Ilowite Shares His Crafthttps://practicaldermatology.com/news/the-osteopathic-dermatologist-dr-peter-ilowite-shares-his-craft/2458866/Peter Ilowite, DO, Assistant Professor of Dermatology at Mt. Sinai Hospital and Dermatology Residency and an Assistant Professor of Medicine at Touro College of Osteopathic Medicine, both of New York City, spoke at the Atlantic Regional Osteopathic Convention (AROC
- Ferndale Healthcare Launches Vegetarian Formula of Heliocarehttps://practicaldermatology.com/news/ferndale-healthcare-launches-vegetarian-formula-of-heliocare/2458868/Ferndale Healthcare® has introduced to its existing Heliocare® line a new vegetarian formula, free of gluten and artificial dyes. The new Heliocare® Ultra Dietary Supplement contains a powerful blend of antioxidants, including Fernblock®
- Report Predicts Growth in Global Dermatology Diagnostic Devices Market 2015-2019https://practicaldermatology.com/news/report-predicts-growth-in-global-dermatology-diagnostic-devices-market-2015-2019/2458869/A recently published report, Global Dermatology Diagnostic Devices Market 2015-2019, which was prepared based on an in-depth market analysis with inputs from industry experts
- The National Eczema Association Names Amy Fauver New VP For Advocacy & Accesshttps://practicaldermatology.com/news/the-national-eczema-association-names-amy-fauver-new-vp-for-advocacy-access/2458872/The National Eczema Association (NEA) named Amy Fauver as Vice President for Advocacy and Access. The NEA says in this new position, Ms. Fauver will build its advocacy capacity and better leverage the voices of the eczema community, enhancing NEA’s ability to create meaningful changes in ec
- Alphaeon Launches Social Commerce Store for Physician Specialistshttps://practicaldermatology.com/news/alphaeon-launches-social-commerce-store-for-physician-specialists/2458876/ALPHAEON Corporation launched ShoutMD 3.0. ShoutMD is a unique professional and social network that allows board certified physician specialists to share insights, start discussions, and collaborate with their peers with the goal of improving patient experiences and outcomes, according to the com
- FDA Approves Updated Label for Allergan's Teflaro for Treatment of ABSSSIhttps://practicaldermatology.com/news/fda-approves-updated-label-for-allergans-teflaro-for-treatment-of-absssi/2458880/The FDA approved Allergan’s supplemental new drug application (sNDA) to update the label for Teflaro® (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).